RespireRx Pharmaceuticals Inc (fka RSPI)

[ombowstring]

RS e-mailed me as follows (looks like it was 7:26 pm PDT yesterday):

John, I have often told you that Cortex and its personnel are limited to discussing issues which have been PUBLICLY disclosed and simply cannot discuss every issue which you might raise. That is true for all types of shareholders and we cannot answer every question you might have whenever you think of them. Hence, we would be forced to give you a non-answer whenever you touch subjects which have not been disclosed in a previous public disclosure. There are very good reasons that the SEC and stock exchanges have such rules and we need to obey them, no matter how many shares someone owns. I believe Mark did his best to respond to your requests, but often disclosing some of the issues you would like to see aired publicly, may in the end do more damage for competitive reasons or also impact discussions underway with other companies and we often do not want to show our hand in a public forum. The deal with Biovail took 9 months of negotiations to complete, so you can see that there might be issues which you are not considering which could impair our efforts as a business if we were to disclose them every time we get questions. Regards, Roger

To which I replied --

Thanks for responding, my friend. Of course, I understand what you are saying, but there have been many times that I have asked questions that I believe could have been responded to, but were unanswered. So, I don't believe you are batting 1.000 in regard to your statement, "Hence, we would be forced to give you a non-answer whenever you touch subjects which have not been disclosed in a previous public disclosure."

I have indeed written you many e-mails, and I appreciate very much your or Mark's responding to them, but, I believe, not so many as to distract you from your work. Many could have been answered that could have yielded information that I and numerous other shareholders would have found interesting and instructive. And your e-mails are among the most informative information that we receive and contemplate.

I sense an optimism about what Cortex is doing unlike any in the past that the company may finally be on the road to success. Here's hoping the ADHD works out, the jury seems to be split on the sleep apnea indication, but there are many seen and unseen avenues that Cortex might pursue that will lead to gargantuan success.

Thanks again,
JM